Thursday, February 5, 2009

King Pharmaceuticals Offers New Dosage Strengths of Avinza to Provide More Treatment Options for People with Chronic Pain

Feb 5, 2009 - King Pharmaceuticals, Inc. today announced the launch of two new FDA-approved dosage strengths for AVINZA (morphine sulfate extended-release capsules). The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. AVINZA is a long-acting opioid for patients with moderate to severe chronic pain who require around-the-clock pain relief for an extended period of time.

The details can be read here.

No comments: